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Dietary components express a wide range of activities that can affect carcinogenesis. Naturally occurring substances in foods have been shown in
laboratory experiments to serve as dietary antimutagens, either as bioantimutagens or as desmutagens. Dietary desmutagens may function as
chemical inactivaters, enzymatic inducers, scavengers, or antioxidants. Dietary components may also act later in the carcinogenic process as tumor
growth suppressors. Examples of dietary factors acting in each of these stages of carcinogenesis are presented, and potential anticarcinogens such
as the carotenoids, tocopherols, phenolic compounds, glucosinolates, metal-binding proteins, phytoestrogens, and conjugated linoleic acid are
discussed. Individual foods typically contain multiple potential anticarcinogens. Many of these substances can influence carcinogenesis through
more than one mechanism. Some substances exhibit both anticarcinogenic and carcinogenic activity in vitro, depending on conditions.
Epidemiologic research indicates that high fruit and vegetable consumption is associated with lower cancer risk. Little research has focused on the
effects of single substances or single foods in man. Realization of the potential of foodborne substances to reduce the human burden of cancer will
only be achieved with better measurement of dietary exposures and funding of multidisciplinary research in this area commensurate with its
importance. - Environ Health Perspect 103(Suppl 8):177-184 (1995)
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Introduction
Few persons doubt that diet plays a large
role in carcinogenesis. Doll and Peto (1)
estimated in 1981 that diet can account for
up to 70% ofall avoidable cancers. Recent
reevaluations have not challenged the rela-
tive importance of diet (2). Knowledge of
the actual active substances and mecha-
nisms ofeffect remain limited. We are still
at a stage comparable to three blind men
attempting to determine the physical
nature of an elephant, with a relatively
small group ofscientists examining specific
aspects ofcarcinogenesis in relative isola-
tion. Realization ofthe potential ofdietary
prevention of cancer will require major
investments in four areas. One of these is
the identification ofthe substances in foods
that can be protective. The promise and
current knowledge in this area are reviewed
later. Second, there is an acute need for the
development of nutrition and cancer
research units that promote multidiscipli-
nary approaches toward research on diet
and cancer. A critical mass of scientists
working together could spearhead scientific
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advancement across basic biochemical and
epidemiologic research axes. A third
important area is that ofexposure measure-
ment. The Achilles heel ofdiet and cancer
epidemiology is the underdeveloped state
oftools to measure or estimate these expo-
sures. Cognitively smart dietary assessment
tools that succeed in capturing complete
information from large proportions ofthe
population of interest are sorely needed.
The development ofbiomarkers ofdietary
exposures could help but not eliminate the
need for subject assessment (3). Accurate
information on the long-term quantitative
exposure levels and habitual diets of indi-
viduals is fundamental to scientific
advancement. Finally, we need to invest in
programs that educate and stimulate indi-
viduals to select healthier diets based on
up-to-date knowledge ofpreventive foods.
The past two decades have witnessed a
major effort to discover which elements of
our diet affect carcinogenesis and by what
mechanisms. Initial interest focused on car-
cinogenic effects of diet. More recent
research includes increased focus on dietary
prevention of cancer. Epidemiologic
research remains the most powerful tool
for determining the role ofnutrition in the
etiology of cancer in human populations.
The reasons for this are related to the need
for measurement of long exposures to
active substances in the diet, long lags
between exposure to risk factors and dis-
ease, ethical constraints on human experi-
mentation, and the plethora of dietary
factors of interest. Such complications,
which may translate into problems with
measurement error, lag-time uncertainty,
collinearity, and weak single-factor associa-
tions in epidemiologic studies, are reviewed
elsewhere (4).
This paper surveys current knowledge
regarding anticarcinogenic agents in foods.
Potential mechanisms of action serve as a
framework for discussion ofepidemiologic
findings for specific agents. General weak-
nesses ofepidemiologic studies on diet and
cancer are addressed and strategies to over-
come them are proposed.
Proposed Mechanisms for
Dietary Anticarcinogens
Laboratory studies provide most of our
information about potential mechanisms of
action ofdietary anticarcinogens. A review
ofthe many laboratory studies on potential
mechanisms ofanticarcinogens reveals that
many chemicals possess multiple modes of
action. In Table 1, dietary components
known to exert some form ofanticarcino-
genic activity are presented, along with
their mechanisms of action. Most anticar-
cinogens also show potentially detrimental
effects such as mutagenicity, comutagenic-
ity, cocarcinogenicity, or tumor promotion
under certain circumstances. In addition,
both mutagens and antimutagens have been
found in mostwell-studiedwhole foods.
Translating the large and complex body
of knowledge on potential mechanisms
into predictions ofthe health consequences
ofspecific dietary interventions in humans
is a great challenge. In the following sec-
tion, we briefly review the mechanisms by
which anticarcinogenic agents present in
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Table 1. Selected dietary anticarcinogens and their postulated mechanisms.
Mechanism
Desmutagen
Direct chemical Enzyme Binding Tumor growth
Compound Bioantimutagen inactivater modulator scavenger Antioxidant suppressor References
Ascorbic acid (vitamin C) - - X _ X X (27,63)
BHA(2(3)tert-butyl-4-hydroxyanisole) - - X - X _ (64)
Calcium (with vitamin D) - X - _ - X (65)
Carotenoids(P-carotene) - - - - X X (34,35)
Conjugated linoleic acid - - - - - X (60)
Coumarins - - X - - _ (15)
Dithiolthiones - - X - - _ (66,30)
Dietaryfiber - - - X - - (67)
Flavonoids (see phenolics) - - X _ X X
Folic acid - - - - - X (68)
Genistein (see phytoestrogens, phenolics) - - X - X X
Indoles (indole-3-carbinol) - - X - _ X (15,69)
Inositols (inositol hexaphosphate) - - - - X _ (31)
Isothiocyanates (benzyl isothiocyanate) - - X - _ X (15,70)
Lignins (curcumin/turmeric, sesamol) - - - - X _ (71)
Omega-3 fatty acids - - - - - X (61)
Organosulfur compounds:Allium sp. - - X _ X X (18)
(see also indoles, isothiocyanates)
Phenolics (flavonoids, tannins, catechins) X - X _ X X (12,31,43,50)
Phytates (phytic acid) - - - - X - (73)
Phytoestrogens (from isoflavones, lignans) - - ? X (31)
Porphyrins (chlorophyllin) - - - X X X (24)
Protease inhibitors - - - - - X (74)
Retinoids (vitamin A, retinol) (see also carotenoids) - - - - - X (75,76)
Saponins - - - - _ X (31)
Selenium - - - - X X (57,77)
Terpenoids:noncarotenoid
(monoterpenoids, limonoids) - - X - _ _ (70,72)
Tocopherols (vitamin E) - X _ - X _ (78)
Vanillin X - - _ _ _ (12)
the human diet may act. Anticarcinogens
will be organized by mode of action,
adapted from the schemata found in a
recent review of antimutagenic agents in
the diet (5). Detailed information on the
various test systems used to detect antimu-
tagenicity is provided in other recent works
(6-8). In addition to antimutagens, we will
include agents that act postinitiation and
refer to these as tumor growth suppressors.
While prevention of progression of late-
stage events to neoplasms by both macro-
and micronutrient manipulation has been
demonstrated, this review focuses on
specific compounds found in the diet.
DietaryAntimutagens
Components of the diet can act at any of
the various stages of carcinogenesis. Those
that block mutagenesis prior to tumor
development can be considered antimuta-
gens. Antimutagens in the diet can be
broadly classified into two groups, the
bioantimutagens and the desmutagens, the
former acting on DNA and the latter not
affecting genetic material directly (9).
Bioantimutagens. The bioantimuta-
gens are naturally occurring substances that
reduce mutant yield by acting on the DNA
repair or replicative processes. These com-
pounds act after a DNA adduct has formed
but before the DNA lesion is fixed into a
mutation. Because these compounds alter
the mutation process, they have also been
dubbed true antimutagens (9). Bioanti-
mutagens exhibit several specific modes of
action in the bacterial test systems com-
monly used for screening. They may a)
inhibit the induction of strand-on-strand
DNA repair, reducing replication of
mutated strands; b) in cells containing
mutations, make the "proofreading" in
repair more like that seen in normal cells;
or c) accelerate the recombination strand-
on-strand repair rate, thus reducing the
number ofmutated strands (10).
An example of a bioantimutagen is
vanillin, present in vanilla beans, which
appears to enhance postreplication recom-
binational repair under certain conditions
(11). This results in a decrease in the num-
ber of mutants recovered after exposure of
a cell culture to mutagen. Vanillin has been
tested in vitro using a variety ofcell types,
from Escherichia coli to mammalian cells,
and against a wide variety ofphysical and
chemical agents, such as N-nitroso com-
pounds, heterocyclic amines, and small
nonplanar alkylators. The antimutagenicity
ofvanillin is not universal. Review of31 in
vitro assays found that vanillin reduced
mutagenicity in 17 and showed no effect in
5; in 9 assays, however, mutagenicity was
enhanced (12).
In addition to the complexity of the
antimutagenicity exhibited in in vitro test
systems, many ofthe bioantimutagens can
exhibit genotoxicity under certain testing
conditions (13). The effectiveness ofmany
of these compounds in blocking carcino-
genicity in animals and man has not been
adequatelystudied.
Desmutagens. Desmutagens encompass
all agents that affect mutagenicity through
mechanisms other than DNA repair or
replication. These mechanisms include
enzyme induction, mutagen scavenging,
and blocking of mutagen activation. As
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Table 1 reflects, many more desmutagens
are known than bioantimutagens. Like
bioantimutagens, they suppress the appear-
ance of mutants under assay conditions.
Unlike bioantimutagens, however, they cre-
ate this effect without directly affecting the
genetic material (5). This can occur
through alteration ofthe survival ofmutant
cells or by altering the dose of mutagen
delivered to normal cells. The net effect is a
reduction ofaltered DNA levels per cell.
The next few sections discuss several specific
mechanisms ofaction fordesmutagens.
ChemicalInactivaters andEnzymatic
Modulators. Chemical inactivaters and
enzymatic modulators are agents that pre-
vent the formation of mutagens or their
activation to more potent forms (5).
Chemical inactivaters can act directly to
inhibit the formation ofactive carcinogenic
compounds, such as the conversion of
nitrosamines from nitrite in the stomach.
Modulators can act through enzyme sys-
tems by inducing phase I or phase II
enzymes or by altering the balance ofdif-
ferent enzyme activities. These agents
range from ascorbic acid to glucosinolates
from cruciferous vegetables and the allium
compounds found in garlic.
The anticarcinogenic potential ofcru-
ciferous vegetables has been related to two
sets of compounds found exclusively in
these vegetables: dithiolthiones and glu-
cosinolates. Dithiolthiones are among the
strongest inducers of phase II enzymes,
including quinone reductase, glutathione
transferase, and glutathione reductase (13).
They have been found to decrease colon
and liver cancer in rats but increase DNA
damage in mice. The glucosinolates
are hydrolyzed into isothiocyanates and
indole derivatives, both ofwhich have also
been implicated as stimulators of mixed-
function oxidase activity through the
P450 cytochrome system. Isothiocyanates
have been shown to reduce mammary
and pulmonary tumorigenesis in rats
and mice (14-16). They are also phase II
enzyme inducers.
Indole 3 carbinol, when administered
simultaneously with aflatoxin in animal
studies, reduces aflatoxin B1 binding to
DNA. When the indole is given preinitia-
tion, liver carcinogenesis is also reduced
(17). However, ifadministered later, car-
cinogenesis is enhanced. This illustrates the
complexity of the interaction ofdietary
compounds in aparticular test system.
Garlic extract and many of its compo-
nents exhibit activity against a wide range
ofchemical mutagens and radiation (18).
Increased glutathione S-transferase activity
in one or more organs has been shown in
mice and rats administered garlic compo-
nents such as diallyl sulfide and allyl-
methyltrisulfide. Evidence of effects on
mixed-function oxidase and P450 enzyme
systems has also been reported. In addi-
tion to effects on enzymes, it appears that
garlic compounds may scavenge radicals
and inhibit promotion-mechanisms
considered later in this review (18).
The enzyme inducers as a class have
some promising characteristics. They usu-
ally act against a broad range ofmutagens.
In addition, enzyme inducers need not
necessarily be present simultaneously with
a promutagen to be effective in blocking its
activity. Unfortunately, these compounds
exhibit deleterious effects under certain cir-
cumstances. For example, active com-
pounds in cruciferous vegetables appear to
act as cocarcinogens in some rodent mod-
els (19,20). Similarly, the inducers ofP450
may be beneficial in one circumstance and
not in another, as this enzyme system is
involved not only in detoxification but also
in the activation ofsome carcinogens (5).
An additional complication is that many of
the compounds that induce phase II
enzymes may be carcinogenic at high con-
centrations. This is thought to arise from
the electrophilic nature of most phase II
inducers (21,22). While the overall effect
ofenzyme inducers in the diet is likely to
be anticarcinogenic, assessing their effect
on specific carcinogens ofinterest demands
careful evaluation.
Scavengers (Non-02). Scavengers bond
with mutagens to render the mutagen inca-
pable ofreacting with DNA. The mutagen
generally remains intact during this process
(5). One class of chemicals that forms
complexes with mutagenic compounds is
the porphyrins, including chlorophyllin
(23). Chlorophyllin inhibits the muta-
genicity of a variety ofdietary mixtures as
well as individual large planar mutagens
(e.g., aflatoxin B1, benzo[a]pyrene) in
vitro. It has little or no effect against small
nonplanar carcinogens (5). Additionally,
the urinary mutagenicity ofhumans ingest-
ing cooked ground beefhas been lowered
with co-administration of chlorophyllin
(23). Chlorophyllin has been shown to
complex with polycyclic compounds,
thereby blocking their mutagenic potential
(24). As with the other categories discussed
so far, porphyrins do not appear to be uni-
versallybenign. Chlorophyllin, forexample,
tested positive as a tumor promoter in the
rat-dimethylhydrazine colon carcinogenesis
model (25). One would expect that for
compounds in this category to be effective,
they should be co-administered with the
mutagen. This may make these agents less
effective for dietary preventive purposes
than the enzymatic inactivaters, particu-
larly for certain scavengers that are not
normally consumed with most meals.
Antioxidants and Free Radical
Scavengers. Antioxidants exert their effect
by donating electrons to unstable oxygen
species generated from endogenous
processes or formed as a result ofradiation
or chemical exposure. This property could
protect against cancer in many ways.
Preempting oxidative attack on chemical
bonds at other points in the cell, including
DNA helices, may reduce the incidence of
mutations arising from oxidant-induced
DNA lesions. Blocking the stimulation of
cell division attributed to oxidants may also
lead to a reduction in the rate ofmutation
(26). Beyond antimutagenic effects, antiox-
idants help to maintain the physical
integrity of cell membranes and normal
production ofmembrane-derived cellular
regulatory agents. They may also prevent
collateral damage caused by free radicals
produced by cells ofthe immune system
during attack on foreign materials.
Vitamin C and carotenoids possess well-
documented immuno-stimulatory effects
that may stem, at least partly, from the
antioxidant properties just described.
Ascorbic acid (vitamin C) is an example
ofa water-soluble extracellular antioxidant
with intriguing dual properties. On one
hand, it quenches singlet oxygen and
assorted free radicals; on the other hand, it
preserves the function ofother antioxidant
compounds, notablyvitamin E, by reducing
them back to active form after they have
quenched free radicals (27). Carotenoids
such as 5-carotene and lycopene illustrate
lipid-based antioxidants.
A major advantage of the antioxidants
is that they are generally effective against a
wide range of mutagens, both exogenous
and endogenous. While most have no
known major adverse effects, their redox
potential may facilitate some pro-oxidant
activity. In the presence ofiron, for exam-
ple, ascorbic acid can enhance carcinogene-
sis under experimental conditions (28). A
further interesting property ofantioxidants
is that they may exhibit antipromotional as
well as antimutagenic activity through
inhibition ofoxidant-stimulated cell divi-
sion (29). Such activity overlaps with that
of the final category of anticarcinogens,
substances that suppress tumorgrowth.
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Tumor Growth Suppressors
Tumor growth suppressors exert their
effects at late stages in the carcinogenic
process, i.e., postinitiation. The substances
in this category express a wide range of
effects, including interference with promo-
tion (when coadministered with a known
tumor promoter) or interference with the
ability of the tumor to grow and invade
other tissues. Protease inhibitors found in
soybeans, grains, and other vegetables are
examples of this class ofsubstances (30).
They are believed to work by interfering
with proteases used by neoplastic cells for
destruction ofthe extracellular matrix, cel-
lular detachment, and invasion ofmetasta-
tic cells into new sites. Further examples of
tumor inhibition are provided by phytoe-
strogens and garlic oil. Phytoestrogens
bind to estrogen receptors, blocking the
binding of other more potent estrogens
without stimulating cellular growth (31).
Garlic oil significantly reduces skin tumor
yield in rodents when coadministered with
promoting agents (18).
In summary, dietary anticarcinogens act
via several mechanisms: DNA repair and
replication, chemical or enzymatic inactiva-
tion, scavenging ofmutagens, antioxidant
activity, and tumor inhibition. As more data
accumulate, it is becoming apparent that
many foods contain more than one com-
pound and that many compounds exhibit
more than one mechanism (Table 1). The
anticarcinogenic picture painted by labora-
tory studies is often complex, making pre-
diction of the effect on living humans
impossible withoutepidemiologicfindings.
Evidence for Association
of Cancer with Specific
Food Components
Epidemiologic studies examining relation-
ships between the intake offruits and vege-
tables provide consistent evidence of
protective effects. A review ofthe 156 stud-
ies by Block (32) examining intakes of
fruits and vegetables showed lower rates of
cervical, ovarian, lung, esophageal, oral
cavity, larynx, pancreatic, stomach, colon,
rectal, bladder, and breast cancers in people
who consumed fruits or vegetables rela-
tively more frequently than those who did
not. While indicating the wisdom ofgen-
eral advice to eat more fruits and vegeta-
bles, use of such wide dietary constructs
precludes more specific recognition of
actions and interactions. Only recently,
however, has epidemiology begun to turn
from broadly defined food categories to
explore the active ingredients in these
foods. Research now should focus on the
isolation of specific agents in fruits and
vegetables (as well as in other foodstuffs)
that impact cancer risk.
Vitamins andRelatedCompounds
Specific substances from plant sources that
have come under scrutiny because of their
known physiologic importance, high con-
sumption levels, and antioxidant potential
include carotenoids, tocopherols (vitamin
E), and ascorbic acid (vitamin C). The
carotenoid family includes over 500
members, the best known ofwhich is the
provitamin, 5-carotene.
Carotenoids. The rich array ofconju-
gated double bonds characteristic of
carotenoids inspires interest in their poten-
tial as free radical scavengers. The range of
antioxidant activity exhibited by individual
carotenoids in the laboratory varies greatly.
Research has concentrated largely on
,-carotene, although some other caroten-
oids (e.g., lycopene, lutein) show greater
singlet oxygen-quenching potential (33).
Studies of the effects of n-carotene on
tumor formation in animals yield inconsis-
tent results. Krinsky (34,35) presents an
overview ofexperimental findings on the
effects of n-carotene on chromosome
breaks, sister chromatid exchange, and
tumor growth. He attributes the mixed
results to difficulties in assuring significant
uptake ofcarotenoids in most animal mod-
els. It is also unclear whether ,-carotene or
its retinoic derivatives are acting in these
tests. The administration of carotenoids
has, however, shown impressive results in
the hamster, including decreased incidence
and even regression oftumors.
Evidence from human studies is more
consistent. Block (32) notes that at least
32 studies have examined relationships
between consumption of foods rich in
carotenoids and/or ,-carotene levels in
serum and lung cancer risk, with 30 of
these studies showing a protective relation-
ship. In a similar review, Canfield et al.
(36) relate that a statistically significant
inverse association between lung cancer
and estimated dietary 3-carotene intake
appears in 16 published studies, while
7 studies show a similarly significant asso-
ciation for 5-carotene measured in serum.
The same reviewers note that 5 of 6
studies found significant associations of
cervical dysplasia with low dietary and/or
serum 5-carotene levels. In addition, I-
carotene administration was efficacious
against oral leukoplakia in at least three
clinical trials (37,38).
More recent findings muddy the picture.
3-Carotene, whether alone or in combina-
tion with vitamins C and E, failed to
reduce the recurrence ofcolon polyps in a
3-year clinical trial (39). In addition,
Finnish smokers receiving ,B-carotene sup-
plements for 5 to 8 years showed no reduc-
tion in lung cancer risk-in fact, risk
increased, particularly among older sub-
jects (40). The ability to draw firm conclu-
sions from either study is limited by
methodological considerations. In both
studies, the supplementation period was
short and the supplementation may have
come too late in the neoplastic process to
influence the outcome. More positive
results were observed in supplementation
studies on gastric cancer, wherein mixtures
of 3-carotene and vitamin E reportedly
lowered rates ofoccurrence (41).
Different foods contribute different
levels ofcarotenoids. Carrots contain pri-
marily ,B-carotene, broccoli contains lutein
and 5-carotene. Tomatoes and crustaceans
are rich sources of lycopene. Raw guava
and watermelon also provide large concen-
trations oflycopene. Lutein can be found
in very high amounts in chicory, chives,
kale, collards, cress, and other greens. The
major sources ofcarotenes in the American
diet are carrots, tomatoes, sweet potatoes,
yellow squash, spinach, and cantaloupe
(42). These six foods account for 70% of
carotenoids in the diet. Romaine lettuce,
broccoli, spinach and iceberg lettuce con-
tribute approximately another 10%. The
carotenoids deserve more focused research
attention to clarify their activities and more
closely examine the effects ofcarotenoids
other than 3-carotene.
Tocopherols. The natural tocopherols
include eight compounds that are com-
monly known as vitamin E. a-Tocopherol
is the predominant component. Most vita-
min E is derived from vegetable oils, nuts,
sunflower seeds, andwhole grains.
A number ofstudies have examined the
relationship between ax-tocopherol or total
vitamin E levels in blood with cancer. The
majority ofthese studies is consistent with
a protective association for all cancers as a
group; specific cancer types with evidence
ofprotective association include gastroin-
testinal, lung, colon, breast, cervical, and
oral cancers. Many studies reporting associ-
ations for vitamin E reported similar asso-
ciations for one or more other fruit- and
vegetable-associated antioxidants aswell. It is
notable that the previously mentioned clin-
ical trial of 3-carotene's effect on recurrence
of colon polyps also included trials of
Environmental Health Perspectives 180DIETARYANTICARCINOGENS
vitamin C and E supplementation, with
similarly negative results (39). While the
Alpha-Tocopherol Beta-Carotene (ATBC)
Trial did not show a protective association
ofvitamin E with lung cancer, prostate
cancer mortality was significantly lower in
the vitamin E-supplemented group (40).
PhenolicCompounds
The phenolic compounds include simple
phenols, phenolic acids, hydroxycinnamic
acid and its derivatives, and flavonoids.
The most biologically active phenolic sub-
stances are thought to be the flavonoids,
the proanto- and anto-cyanins, and the
catechins. Flavonoids provide an extreme
example of disagreement between labora-
tory-based test systems. Evidence ofbacter-
ial mutagenicity implicates flavonoids as
potential carcinogens, yet in vivo studies
yield little evidence of carcinogenicity.
Rodent-based studies involving administra-
tion ofknown carcinogens provide evidence
ofprotection against epithelial and colon
tumorigenesis by flavonoids (43). Animal
experiments also indicate anticarcinogenic
activity for several specific catechins. Tea
catechins, for example, reduce tumorigenesis
and tumor growth in mice (44).
Phenolic compounds could affect car-
cinogenesis through a number of mecha-
nisms. These compounds may scavenge
carcinogens or free radicals. They may also
block generation ofreactive oxygen species.
Epicatechin gallate, for example, inhibits
free radical chain reactions of cell mem-
brane lipids and can influence mutagenic-
ity and DNA-damaging activity (45).
Some flavonoids bind to estrogen recep-
tors. It has been argued that by this bin-
ding they act on the regulation of gene
transcription and may protect against
estrogen-related cancers (46). Phenolic
compounds, in general, affect phase II
enzymes. It remains unclear whether such
induction by phenolic compounds affects
carcinogenesis in vivo (47). Phenolic com-
pounds may also reduce cellular prolifera-
tion through the modulation of protein
kinase C activity. A few phenolics may pos-
sess bioantimutagenic properties (12).
Estimates of the amounts consumed
daily vary widely. Based on the average diet
of a Dutch population, tea provides the
greatest amounts of flavonoid (61%);
onions and apples are the next greatest
sources, providing 13 and 10%, respectively
(48). Tea leaves may have catechin concen-
trations that represent up to 30% of the
dry weight of the tea leaf (45). Allium
vegetables (leeks, shallots, scallions, garlic,
and onions) range in their flavonol content
from none to more than 1 g/kg ofvege-
table. Shallots have uniformly high concen-
trations, but onions range widely, with no
measurable amounts in white onions and
high levels in yellow onions (49).
The mechanisms hypothesized as
influencing carcinogenicity have hardly
been studied in epidemiologic efforts
directed at specific phenolic compounds.
One exception is a recent Dutch study
(50) in which estimated dietary intake of
flavonoids showed no association with
lung, gastrointestinal, or all-cause cancer
mortality incidence in a male cohort fol-
lowed for 5 years. The modest size and
short follow-up period ofthe study greatly
limit its power, however.
Despite the wealth ofstudies on food
groups such as fruits and vegetables and
cancer, there is a dearth ofstudies on active
ingredients in foods. This is largely because
ofthe lack ofreliable edited food composi-
tional databases for phenolic compounds.
Glucosinolates
Glucosinolates are present exclusively in
vegetables of the family Cruciferae, espe-
cially in the genus Brassicaceae. This
includes cabbages, broccoli, brussels sprouts,
and cauliflower. Differences in cabbage
consumption have been associated with
differences in colon and breast cancer
mortality across Europe (51).
The modulation of carcinogenesis by
the consumption ofBrassica vegetables has
been investigated in laboratory animals
challenged with carcinogens. The compari-
son oftumor development in animals with
and without cabbage supplements provides
evidence ofan effect on the production of
some tumors. Mammary tumors, particu-
larly in mice and rats, seem to be reduced
upon the addition of5 to 20% ofcabbage,
byweight, to the diet (22,52).
The glucosinolate content of foods
varies from species to species, from crop to
crop, and from lab to lab. The amount of
thiocyanate, for example, in various
Brassica ranges as much as 7-fold within a
species. Their average concentrations in
milligram per kilogram fresh weight vary
up to 4-fold between species. Among the
subspecies, late sowing and younger sam-
ples show a larger percentage ofacetonitrile
extracts from these vegetables, ranging
from 4.6 to 15.6% ofdryweight (53).
A number of activities related to glu-
cosinolates and dithiolthiones have been
reviewed earlier. Another proposed action
is related to the Brassica component
indole-3-carbinol, which acts as a modu-
lator ofestrogen metabolism in a way that
reduces carcinogenesis. The 2-hydroxy-
estrone shows minimal estrogenic activity,
whereas the 16-hydroxyestrone is both
genotoxic and exerts full estrogenic
potency (54). The in vivo effect of many
compounds implicated in the carcino-
genic process on this pathway has been
demonstrated (55). Indole-3-carbinol
enhances urinary excretion of2-OH estra-
diol metabolites, whereas carcinogens
such as dimethylbenz[a]anthracene and
benzo[a]pyrene reduce the 2-OH estradiol
metabolite levels. Alcohol and the polyun-
saturated fatty acids linoleic and arachi-
donic, on the other hand, increase the
excretion of 16-OH metabolites. The
chemoprotective effects of indoles have
received little attention.
MetalsandMetal-bindingProteins
Extracellular metal-binding proteins may
act as antioxidants by rendering metals
needed to catalyze oxidant-releasing reac-
tions unavailable. They may also quench
free radicals directly. Prominent extracel-
lular metal-binding proteins include lacto-
ferrin, transferrin, ceruloplasmin, and
haptoglobins.
Selenium forms the centerpiece of the
best known and most heavily studied met-
alloenzyme antioxidant system, selenium
glutathione peroxidase. Other less well-
characterized selenoenzymes may play
equal or greater roles as antioxidants in
vivo, however (56,57).
Decreased tissue selenium levels have
been reported in case-control studies of
many cancer types. In most studies it is
unclear whether selenium levels fell prior
to or following disease. A recent prospec-
tive study found a significant inverse rela-
tionship oftoenail selenium concentration
and lung cancer in a Dutch cohort (58).
The relationship was much stronger among
subjects with low estimated dietary vitamin
C intakes, and somewhat stronger in the
low P-carotene subgroup. Other, extracel-
lular metal-binding proteins have received
less attention in human population studies
than have selenoenzymes.
Phytoestrogens
Given the established associations between
estrogens and certain cancers (breast,
endometrial, ovarian), the theoretical
importance of phytoestrogens is clear.
Promotional activity could be expected for
some cancers such as estrogen-sensitive
breast tumors and inhibition for others
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such as prostate tumors. The potential
impact of phytoestrogens is tempered by
their low potency relative to estradiol. In
theory, the competition of low-potency
phytoestrogen with high-potency estradiol
for estrogen receptors may have a net anti-
estrogenic effect. A Singapore case-control
study attributed an inverse association
between breast cancer and consumption
of soy products to phytoestrogens (59).
Phytoestrogens often belong to classes of
compounds with more general anticarcino-
genic effects. They may act through mech-
anisms typical ofother anticarcinogens in
those classes in addition to estrogen recep-
tor-mediated antipromotional effects. The
heavily researched phytoestrogen genistein,
for example, is a member ofthe flavonoid
family and shares antioxidant and antipro-
motional characteristics associated with
that family ofcompounds. While substan-
tial in vitro experimental data is available
for some phytoestrogens, epidemiologic
studies specifically targeting phytoestrogens
are currently lacking.
ConjugatedLinoleicAcidand
Omega-3 FattyAids
A mixed isomeric form of linoleic acid,
conjugated linoleic acid, may act as a tumor
inhibitor. Administration to carcinogen-
exposed rats reportedly significantly
reduced the incidence ofmammary tumors
(60). No human studies relating conju-
gated linoleic acid intakes to risk ofdisease
are available. Turkey and red meats, milk,
and cheese form the primary dietary
sources ofconjugated linoleic acid. These
foods also serve as sources ofsimple linoleic
or arachidonic acid, which have been
implicated in tumor promotion.
Omega-3 fatty acid administration is
generally associated with modest-to-
significant tumor inhibition in animal
models. Most studies employ a mix of
omega-3 fatty acids rather than one specific
type. Marine fish comprise the major
dietary source ofomega-3 fatty acids. Fish
oil supplementation is associated with
reduction of mammary tumorigenesis in
rodent models (61). Human epidemio-
logic evidence is largely based on non-
specific exposures such as fish consumption
and contains equivocal results (62).
Dietary Modulators: General
Considerations and
Research Needs
One crucial caveat in many studies of
specific dietary factors is the uncertainty
about whether an observed association is the
product ofa carcinogen, an anticarcinogenic
effect ofthe specific exposure in question, or
ofsome other covarying exposuress. This is
particularly relevant for potential dietary
anticarcinogens, since most occur largely in
fruits and vegetables. Supplementation trials
provide a way around the problem; over 25
intervention studies are now under way for
various antioxidants, alone or in combina-
tion. The number ofpotential anticarcino-
genic agents in the diet identified even in
this brief review is clearly too large for
specific trials of each agent, let alone all
possible combinations.
Calculating exposures based solely on
those foods that contain the highest con-
centrations ofa substance may be mislead-
ing if other foods that contain relatively
low concentrations of the substance are
consumed in greater quantities. This situa-
tion can arise when complete food compo-
sition data are lacking. Data are often
particularly spotty for the less publicized
dietary factors. In general, information on
concentrations ofanticarcinogens in food
is not widely available. Furthermore,
reported species concentrations may not be
predictive ofthe concentrations ofsamples
from different cultivars. These considera-
tions combine with more general problems
such as reliable and precise measurement of
portion size and frequency to point out the
inherent limitations of studies based on
questionnaire data. Such studies contribute
the bulk ofthe epidemiologic literature on
dietary agents and cancer to date.
No single compound is likely to affect
all carcinogens. In addition, it may be the
combination ofdifferent compounds and
different mechanisms ofthose compounds
that is responsible for the effects offood
on cancer seen in epidemiologic studies.
Further, we need to be concerned with
undesirable side effects ofcompounds used
for cancer prevention. Those compounds
or foods that are most beneficial for adults
in the quest to avoid cancer may not be
appropriate in the diet ofpregnant women
and children. While the retinols, for exam-
ple, appear to be beneficial for the preven-
tion of cancer, some are also teratogens.
We know little about the activities ofthese
substances in vivo in combination with the
other components of a normal diet. Only
intensified research will reveal their true
benefits for human health.
Research since Doll and Peto's sugges-
tion that up to 70% ofall cancers may be
diet related (1) has certainly not diminished
interest in dietary factors as potential keys to
carcinogenesis. In fact, Austoker (2) recently
concluded that dietary modifications might
potentially reduce overall cancer incidence
by as much as two-thirds based on current
evidence. What has become clearer in the
intervening years is the complexity of the
diet-cancer relationship. Research contin-
ues to introduce new compounds or new
activities ofold compounds as factors in the
relationship. Furthermore, the discoveryand
understanding ofinteractions-positive and
negative-between compounds active in the
cancer arenahave barely begun.
Only a few human cancers show a
clear-cut association with specific dietary
factors. Part of the problem undoubtedly
lies in the poor quality of most of our
exposure measures. Another part of the
problem probably arises from failure to
account for modifying or confounding fac-
tors (either by design or due to incomplete
knowledge of the factors involved). In
addition, logistical difficulties associated
with the long latent period ofmost and the
relative rarity ofsome types ofcancer make
prospective studies difficult. Much of the
problem, however, also probably lies in the
inherent nature ofthe association between
diet and cancer, which is in fact not one
association but a web of intermingled
causal pathways. The challenge is to iden-
tify those factors that, individually or in
tandem, are amenable to practical interven-
tion. This will require research and provi-
sion of support commensurate with the
extent of the problem. To return to the
analogy ofthe blind men and the elephant,
we may envision the elephant as the popu-
lation at risk ofdiet-related cancer. The
provision ofglasses, in the form of better
measurement tools for dietary exposures,
would largely restore the vision ofthe blind
men (and women) now groping with this
puzzling animal. Thus unblinded, closer
cooperation in the form ofinterdisciplinary
research will further sharpen our view.
Effective intervention to preserve the
health and longevity ofthe elephant may
then fallwithin our grasp.
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